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leukocytesVariants of the FTO gene show strong association with obesity, but the mechanisms behind this association
remain unclear. We determined the genome wide DNA methylation proﬁle in blood from 47 female preado-
lescents. We identiﬁed sites associated with the genes KARS, TERF2IP, DEXI, MSI1, STON1 and BCAS3 that had
a signiﬁcant differential methylation level in the carriers of the FTO risk allele (rs9939609). In addition, we
identiﬁed 20 differentially methylated sites associated with obesity. Our ﬁndings suggest that the effect of
the FTO obesity risk allele may be mediated through epigenetic changes. Further, these sites might prove
to be valuable biomarkers for the understanding of obesity and its comorbidites.
© 2011 Elsevier Inc. All rights reserved.1. Introduction
Obesity has a strong heritable component that is only in part
explained by known single nucleotide polymorphisms (SNPs) [1–4].
The gene that has the strongest association with human obesity is
the fat mass and obesity associated (FTO) gene. Although the func-
tional role of FTO remains obscure, it is known that it encodes for
an enzyme able to remove methyl groups from DNA and RNA nucle-
otides in vitrowith highest afﬁnity for single stranded RNAmolecules.
This suggests that the association with obesity could be mediated by
epigenetic mechanisms [5]. One of the central epigenetic mechanisms
is methylation of DNA cytosine residues, which may decrease tran-
scription of genes localized near the methylation site [6]. Interesting-
ly, studies of identical twins have revealed that their DNA
methylation proﬁle diverge with increasing age, which supports the
notion of a major environmental inﬂuence on epigenetic alterations
[7]. Increasing amounts of evidence indicate that DNA methylation
is sensitive to extrinsic factors, such as certain diets and nutrients
[8]. A recent study found that exposure to high-fat diet was not only
associated with peripheral insulin resistance, but also inﬂuenced
DNA methylation of the peroxisome proliferator-activated receptor
gamma, coactivator 1-alpha (PPARGC1A) gene in skeletal muscle
[9]. Other studies have suggested that the methylation level can beience, Biomedical Center, Box
(M.S. Almén).
rights reserved.highly associated with speciﬁc genotypes, which suggest that the ef-
fect of genetic variations can be exerted through epigenetic changes
[10]. One such study by Ling et al. identiﬁed a polymorphism in the
promoter of the NDUFB6 gene that creates a potential new methyla-
tion site that was methylated in elderly. Interestingly, this higher
methylation reduces NDUFB6 transcription, which was associated
with higher peripheral insulin resistance [11]. In a similar way, genet-
ic variations within the MCHR1 gene are affecting DNA methylation
levels in an age dependent manner, which contributes to the age de-
pendent obesity association of these genetic variations [12]. Another
mechanism for the interaction between genetic and epigenetic inter-
action is demonstrated by the linkage between polymorphisms in
genes involved in the metabolic pathways of DNA methylation that
has been associated with changes in these pathways [13{Nordgren,
2011 #113}] and disease [14]. Furthermore, the obesity risk allele of
FTO has been associated with higher methylation of sites within in-
tron one of the FTO gene, which was caused by CpG site creating
SNPs, implying an interaction between genetic and epigenetic factors
for the risk allele [15]. A recent genome-wide investigation study
found that the inter-individual variation in methylation level depends
on both genetic and environmental factors and that the extent of their
inﬂuence differs between sites [16]. Since alterations in the DNA
methylation proﬁle are closely linked to diseases and pathological
conditions including obesity, the determination of such disease-
speciﬁc methylation patterns can prove to be valuable diagnostic
and prognostic biomarkers after clinical validiation [8,17–19]. How-
ever, to be useful in the clinical routine the biomarkers should be
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such methylation marker is the decreased methylation of the IGF2
gene, which can be detected in samples from both colon and periph-
eral blood and in both cases are associated with higher risk for colo-
rectal cancer [20]. Obesity has been linked to changes in DNA
methylation status in blood for several genes through genome-wide
methylation proﬁling studies [21,22] and it has been demonstrated
that such markers can predict weight loss outcome [23]. A previous
study has linked the obesity risk allele of FTO with methylation
changes within the FTO gene itself. However, no previous study has
ascertained how the risk allele affects the methylation status of sites
related to other genes.
In the present study we determined the methylation proﬁle on a
genome-wide scale by sampling DNA from peripheral whole blood
of 47 female preadolescents, including an obese and a normal-
weight group, both of which contains homozygous carriers of both
the FTO normal and risk alleles (rs9939609).
2. Results
We determined the genome wide methylation proﬁle of 47 Greek
female preadolescents (Table 1). The inﬂuence of the FTO allele and
obesity on the methylation proﬁle was identiﬁed by ﬁtting a linear
model that explains the methylation level for each probe on the
array (Fig. 1). The model was corrected for Tanner stage, which is
an estimation of physical development, and white blood cell count.
Four sites associated with the genes KARS/TERF2IP, DEXI, MSI1 and
BCAS3 had a signiﬁcantly increased methylation level in the carriers
of the FTO risk allele and all had a relatively low β-value (Table 2).
One site, in proximity to STON1, had a decreased methylation and a
β-value close to 50 (Table 2). Notably, two of the ﬁve sites, KARS/TER-
F2IP (p=0.0011) and DEXI (p=0.024) were still signiﬁcant when
applying Bonferroni correction, which is stricter than the method
proposed by Benjamini and Hochberg. KARS and TERF2IP share a bidi-
rectional promoter region that lies in conjunction with the identiﬁed
differentially methylated site. Twenty sites were differentially meth-
ylated in the obese individuals compared to the normal-weight con-
trols, 15 sites associated with the genes CERCAM, DPYD, ZNF35,
ZNF362, CBX6, FOXF1, PSMD7, PRRC2C, MSI1, NBPF3, USP5, PLOD2,
TLE3, RPS24 and POLD3 were hypomethylated and the remaining
ﬁve sites, associated with the genes DVL3, COL4A1, H1FX, TSC22D2
and IL12A, were hypermethylated (Table 3). All sites that correlated
with weight category had a low β-value, indicating that the genes
are expressed from most alleles. Notably, the methylation level forTable 1
Demographic data stratiﬁed for weight category and FTO allele.
FTOa Normal-weight Obese P-valued
A
N 12 11
Age(year) 10.55±0.52 11.14±0.88 ns.
Height (cm) 139.83±5.54 148.09±8.57 0.015
Weight (kg) 33.07±3.88 61.94±10.62 b 0.0001
WBCb (103/mm3) 7.84±2.35 6.96±1.68 ns.
Tanner stagec 2(1–3) 3(2–5) 0.02
T
N 12 12
Age(year) 10.53±0.38 10.72±0.47 ns.
Height (cm) 145.83±5.08 154.00±10.38 0.027
Weight (kg) 37.70±4.39 61.38±10.39 b 0.0001
WBCb (103/mm3) 6.80±1.62 7.31±1.61 ns.
Tanner stagec 2 (1–3) 2.5 (1–5) ns.
a — A=risk allele, T=normal allele (homozygous carriers).
b — WBC=White blood cells.
c — estimates physical development, median (range).
d — Indicates p-value for signiﬁcant or non-signiﬁcant (ns.) differences between obese
and normal-weight individuals.
All values given as Mean±S.D.the MSI1 site was signiﬁcantly associated with both weight category
and FTO genotype. However, we could not ﬁnd any signiﬁcant inter-
action (p=0.22, unadjusted) between the FTO and weight category
for the MSI1 site when adding an interaction term to the linear model.
3. Discussion
We have identiﬁed ﬁve sites, corresponding to six genes that differ
in methylation level between homozygous carriers of the normal and
the risk allele of the FTO gene and 20 sites that correlate with obesity
(Table 2). This is the ﬁrst evidence showing that the FTO gene, a de-
methylation enzyme, may inﬂuence the methylation level of other
genes. The FTO protein is structurally similar to the AlkB family of en-
zymes that remove methyl groups from DNA residues [24]. The FTO
protein has a relatively low afﬁnity for cytosine residues in vitro, but
a higher afﬁnity for thymine; it has also been shown to prefer single
stranded DNA [5]. Thus, it remains unclear whether the observed
methylation differences between the two alleles are related to the di-
rect enzymatic function of FTO or is caused by indirect mechanisms.
Interestingly, the two strongest associated sites, KARS/TERF2IP and
DEXI, are located 21 Mbp and 42 Mbp on each side of the FTO gene
on chromosome 16 (Table 2). It is possible that the FTO risk allele af-
fects these genes through changes in the structural or spatial organi-
zation of the chromosome even though the genomic distances are
large. The KARS and TERF2IP sites are associated with a CpG island
near their shared bidirectional promoter [25]. TERF2IP is coding for
a multifunctional protein that is found in the nucleus and cytoplasm
and has a basic function in regulating telomere length, but is also in-
volved in transcriptional regulation and, when residing in the cyto-
plasm, functions as an adaptor protein that enhances NF-kB activity
and is thereby involved in inﬂammatory response [26]. FTO is func-
tionally linked to TERF2IP as they both interact or form complexes
with the DNA repair protein SLX4/BTBD12 according to the interac-
tion database IntAct [EBI-2371551, EBI-2371041] [27]. SLX4/BTBD12
is an endonuclease that is central for several DNA repair mechanisms
and resolves Holliday junctions in the DNA [28]. This interaction is in
concert with the role of TERF2IP in telomere maintenance and the
DNA demethylase activity of FTO. This functional coupling could sug-
gest that the differences we found in the methylation level of the
KARS/TERF2IP site would be a regulatory response to changes in
FTO activity or expression to retain homeostasis between the protein
complex subunits. The KARS gene codes for a soluble enzyme that
catalyzes the attachment of amino acids to tRNA and resides in the cy-
toplasm as well as the mitochondria and nucleus [29]. However, like
TERF2IP, it is a multifunctional protein that is also secreted as a cyto-
kine, which is induced by TNFα stimulation of the cell; adenylates ly-
sine residues of proteins; synthesizes dinucleotides that affect
signaling pathways and regulates transcription factors, such as MITF
and USF2. The risk allele of FTO has been associated with a higher in-
ﬂammation status independent of BMI [30], which could potentially
be connected to the hypermethylation of the KARS/TERF2IP sites.
Also, two SNPs within the TERF2IP locus (rs3784929 and
rs8053257) have been associated with a greater risk of ischemic
stroke in women, a known co-morbidity of obesity [31]. Hence, it
would be of interest to assess the methylation level of the KARS/TER-
F2IP site as a prognostic marker for ischemic stroke and other cardio-
vascular diseases. There is no clear connection for the remaining ﬁve
differentially methylated sites with FTO or obesity. The BCAS3 gene is
an estrogen induced transcriptional coactivator that is over expressed
in breast cancer [32,33]. Both DEXI and STON1 are poorly character-
ized genes. The expression of DEXI is induced by glucocorticoids
and the gene is proposed to have a role in emphysema [34]. STON1
has no clear function, but its paralog STON2 have a role in synaptic
vesicle recycling [35].
Interestingly, the MSI1 site is associated with higher methylation
level for the FTO risk allele carriers, but lower in the obese individuals
Fig. 1. Volcano plots for linear models of methylation levels comparing FTO alleles (a) and obese and lean individuals (b).Volcano plots that show unadjusted P-values vs coefﬁ-
cients (log-fold change of methylation level) for: a. FTO allele (positive coefﬁcients refer an increased methylation in homozygous carriers of the obesity risk allele (A)), b. Obesity
vs normal-weight individuals (positive coefﬁcients refer to an increased methylation in the obese individuals). The green line indicates the adjusted signiﬁcance threshold.
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results suggest that the loss of methylation that we found in the obese
individuals is diminished by the FTO risk allele, which could play a
role in the development of obesity. The MSI1 gene binds to mRNA and
controls its translation [36]. It is a known stem cell marker involved in
cancer progression and is downregulated in the brain of patients with
Alzheimer's disease (AD), which reﬂects a lower number of neuronal
progenitor cells [37,38]. Intriguingly, the FTO obesity risk allele has re-
cently been linked to a higher risk of AD, decreased brain volume and
cognitive impairment in terms of verbal ﬂuency [39–41]. This could be
mediated by the observed epigenetic regulation of MSI1 causing down-
regulation of the gene and consequently a lower number of neuronal
progenitor cells and a decreased cognitive reserve.
In addition to MSI1, we detected 19 sites differentially methylated
in the obese individuals of which seven genes are annotated as regu-
lators of transcription (TSC22D2, CBX6, DVL3, FOXF1, TLE3, ZNF35,
ZNF362) and consequently can control the expression of a large num-
ber of genes. Hence, our results suggest that the epigenetic changes
associated with obesity can potentially propagate into large transcrip-
tional alterations. Most of the genes have no known connection to
obesity or its co-morbidities. However, the gene COL4A1 is essential
for the basement membrane of the extracellular matrix and is impor-
tant for vascular function [42]. Moreover, it has been associated with
myocardial infarction in a Japanese population and has also been
linked to other cardiovascular diseases in mice [43,44]. Therefore,
we speculate that the methylation level of the COL4A1 gene can be
a potential prognostic marker for cardiovascular diseases in obese in-
dividuals. Description for the genes not brought up in the discussion
can be found in Supplementary 1.
Recently, a study identiﬁed four genomic sites where the methyl-
ation level covaries with BMI in an elderly Icelandic group [16]. Out of
these, three are included in our dataset (MMP9, PRKG1 and RFC5)
however the discrepancy for the remaining sites between our studiesTable 2
Differentially methylated genes between carriers of the FTO TT and AA (risk) allele.
Symbol Name Position (NC
KARS/ TERF2IP Lysyl-tRNA synthetase/Telomeric repeat-binding
factor 2-interacting protein 1
Chr16:74238
DEXI Dexamethasone-induced protein Chr16:10944
MSI1 Musashi 1 Chr12:11929
STON1 Stonin 1 Chr2:486602
BCAS3 Breast carcinoma ampliﬁed sequence 3 Chr17:56110
a — Average methylation (beta) value has range 0–100 (low to high methylation).
b — Percentage methylation change in AA (risk) allele carriers relative to average methylat
c — Adjusted for multiple comparisons as suggested by Benjamini and Hochberg [18].depends probably on population differences, study design or the rel-
atively small sample size in both studies. Thus, the results of this and
previous studies need to be replicated in a larger population, which
likely will associate additional methylated sites with both weight
and FTO allele.
Herein, we report that the obesity gene FTO is associated with
methylation changes in several sites, which suggests that the effect
of the risk allele can, at least in part, be mediated through epigenetic
alterations. Moreover, we identify 20 sites that are differentially
methylated in obese individuals. These are candidate biomarkers
which could prove to be of diagnostic and prognostic importance
for predicting the progress of obesity, the development of comorbi-
dites and might contribute to a more personalized treatment.
4. Materials and methods
4.1. Ethics statement
All participants and their guardians gave informed written con-
sent and the study was approved by the Greek Ministry of National
Education (7055/C7-Athens, 19-01-2007) and the Ethical Committee
of Harokopio University (16/ Athens, 19-12-2006).
4.2. Subjects
Twenty three obese and 24 normal-weight preadolescent girls
(Table 1) were included in the analysis from the Greek Healthy
Growth study, as previously described together with sample collec-
tion and preparation procedures [45]. Equal numbers of homozygous
carriers of the FTO obesity risk and non-risk allele (rs9939609) were
randomly selected from the cohort of the previous study for both the
obese and lean group. As the homozygous carriers should presumableBI36) Gene location Avg meth.a Relative effectb P-valuec
612 Intron/uspstream 12.6 8.3% 0.00114
027 Upstream 4.4 12.8% 0.01198
2001 Upstream 23.8 3.7% 0.02417
78 Intron 57.0 −1.3% 0.02417
037 UTR 11.5 5.6% 0.02417
ion.
Table 3
Differentially methylated genes between obese and normal-weight female preadolescents.
Symbol Name Position (NCBI36) Gene location Avg meth.a Relative effectb P-valuec
CERCAM Glycosyltransferse 25 family member 3 Chr9:130222317 UTR 4.9 −13.7% 0.00687
DPYD Dihydropyrimidine dehydrogenase Chr1:98158797 Intron 2.8 −16.4% 0.00796
IL12A Interleukin 12A precursor Chr3:161189517 UTR 2.8 15.5% 0.00844
ZNF35 Zinc ﬁnger protein 35 Chr3:44665023 Upstream 22.2 −5.5% 0.00844
ZNF362 Zinc ﬁnger protein 362 Chr1:33494712 Upstream 5.2 −8.2% 0.00844
TSC22D2 TSC22 domain family 2 Chr3:151609841 Exon 6.4 7.4% 0.00844
CBX6 Chromobox homolog 6 Chr22:37598108 UTR 3.1 −16.7% 0.00844
FOXF1 Forkhead box F1 Chr16:85101840 Exon 4.7 −13.3% 0.00844
PSMD7 Proteasome 26S non-ATPase subunit 7 Chr16:72888397 Intron 7.5 −7.7% 0.01223
H1FX Histone H1x Chr3:130517349 UTR 4.1 10.2% 0.0162
PRRC2C Protein PRRC2C Chr1:169721292 UTR 4.1 −8.4% 0.0188
MSI1 Musashi 1 Chr12:119292001 Upstream 23.8 −3.8% 0.01937
COL4A1 Collagen alpha-1(IV) chain Chr13:109758453 Upstream 9.9 8.6% 0.02313
NBPF3 Neuroblastoma breakpoint family member 3 Chr1:21639319 UTR 5.8 −8.4% 0.02483
USP5 Ubiquitin carboxyl-terminal hydrolase 5 Chr12:6831355 Upstream 4.4 −10.4% 0.03069
PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Chr3:147362332 Upstream 30.8 −5.4% 0.03476
TLE3 Transducin-like enhancer protein 3 Chr15:68177287 UTR 5.5 −6.9% 0.03476
RPS24 40S ribosomal protein S24 Chr10:79463659 UTR 5.8 −10.0% 0.03736
DVL3 Disheveled 3 Chr3:185356123 UTR 4.4 8.5% 0.04529
POLD3 DNA polymerase, delta subunit 3 Chr11:73981434 Intron 6.1 −8.8% 0.04797
a — Average methylation (beta) value has range 0–100 (low to high methylation).
b — Percentage methylation change in obese female preadolescents relative to average methylation.
c — Adjusted for multiple comparisons as suggested by Benjamini and Hochberg [18].
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level) heterozygous carriers were not selected. Genomic DNA was
isolated from peripheral blood using QiaGen Maxiprep kit (Qiagen,
Hilden, Germany) and FTO genotyping procedures were performed
as previously described [46].
4.3. DNA methylation proﬁling
The genome-wide Illumina Inﬁnium HumanMethylation27 Bead-
Chip array (Illumina) which allows interrogation of 27,578 CpG dinu-
cleotides covering 14,495 genes was applied to determine the
methylation proﬁle of genomic DNA isolated and puriﬁed from the
peripheral whole blood. This chip has been shown to give a reliable
and reproducible estimation of the methylation proﬁle on a genomic
scale [47]. First, bisulﬁte conversion of genomic DNA was performed
using the EZ DNA Methylation-Gold™ Kit (Zymo Research) according
to the manufacturer's protocol. Brieﬂy, 500 ng of DNA was sodium
bisulﬁte-treated, denatured at 98 °C for 10 min, and bisulﬁte-
converted at 64 °C for 2.5 h. After conversion, samples were desul-
phonated and puriﬁed using column preparation. Approximately
200 ng of bisulfate-converted DNA was processed according to the
Illumina Inﬁnium Methylation Assay protocol. This assay is based on
the conversion of unmethylated cytosine (C) nucleotides into uracil/
thymine (T) nucleotides by the bisulﬁte treatment. The DNA was
whole-genome ampliﬁed, enzymatically fragmented, precipitated,
resuspended, and hybridized overnight at 48 °C to locus-speciﬁc oli-
gonucleotide primers on the BeadArray. After hybridization, the C or
T nucleotides were detected by single-base primer extension. The
ﬂuorescence signals corresponding to the C or T nucleotides were
measured from the BeadArrays using the Illumina iScan scanner.
The ﬂuorescence data were then preprocessed using the GenomeStu-
dio 2009.2 (Illumina) software, which assigns a quantitative measure
of methylation levels (β-values) for each CpG site, that corresponds to
the ratio between the ﬂuorescence signal from the methylated allele
(C) and the sum of the ﬂuorescent signals of the methylated (C)
and unmethylated (T) alleles, expressed as percentages (0–100%). A
total of 26034 probes were included in the analysis, after discarding
535 probes that did not reach the quality threshold (detection P-
valueb0.01) together with 1009 probes from the sex chromosomes.
The HumanMethylation27k BeadChip data can be found in GEO
with accession number: GSE27860.4.4. Data processing and statistical analysis
All downstream data processing and statistical analyses were per-
formed with the statistical software R (www.r-project.org) together
with themethylumi and limma [48] packages of the Bioconductor pro-
ject [49]. First, data was imported, using the methylumi package and
normalized between arrays with quantile normalization using the
normalizeBetweenArrays function in the limma package with the
method parameter set to “quantile” and otherwise default
parameters.
The relationship between methylation level and variables of inter-
ests were determined using limma's robust regression method (lmFit
command with setting method=“robust”, maxit=1000) to ﬁt the fol-
lowing linear model for each probe k:
Mk ¼ ak þ bkWW þ bkFF þ bkBBþ bkTT þ εk
where Mk is the log2 transformed methylation level (β-value) of
probe k, W is the dichotomized weight category (normal-weight=0
and obese=1), F is the dichotomized FTO allele (TT=0 and
AA=1), B is the white blood cell count, T is the Tanner stage and εk
represents the unexplained variability. The coefﬁcients bkx summa-
rizes the correlation between the methylation level and the variables
of interest. Moderated t-statistics for each contrast and probe was
created using an empirical Bayes model as implemented in limma
(eBayes command). P-values were adjusted for multiple comparisons
as proposed by Benjamini and Hochberg [50] and an adjusted P-
value>0.05 was considered non-signiﬁcant (ns).
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